Cargando…

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis

In April 2017 midostaurin was approved by the US Food and Drug Administration for the treatment of patients with aggressive systemic mastocytosis (ASM). So far, very limited real world data on its efficacy is available. Thirteen patients aged from 48 to 79 years, who received midostaurin in the earl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szudy-Szczyrek, Aneta, Bachanek-Mitura, Oliwia, Gromek, Tomasz, Chromik, Karolina, Mital, Andrzej, Szczyrek, Michał, Krupski, Witold, Szumiło, Justyna, Kanduła, Zuzanna, Helbig, Grzegorz, Hus, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961806/ https://www.ncbi.nlm.nih.gov/pubmed/33799933 http://dx.doi.org/10.3390/jcm10051109

Ejemplares similares

MiRNA as a Potential Target for Multiple Myeloma Therapy–Current Knowledge and Perspectives
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2022)

Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)

Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2018)

Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2022)

Polymorphisms in the Gene Encoding Caspase 8 May Predict the Response to First-Line Platinum-Based Chemotherapy in Locally Advanced or Advanced Non-Small-Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2021)

A case of aggressive systemic mastocytosis with bulky lymphadenopathy showing response to midostaurin
por: Sciumè, Mariarita, et al.
Publicado: (2020)

Chemotherapy-Related Differences in Cognitive Functioning and Their Biological Predictors in Patients with Multiple Myeloma
por: Bury-Kamińska, Magdalena, et al.
Publicado: (2021)

Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2022)

Pleural Neoplasms—What Could MRI Change?
por: Szczyrek, Michał, et al.
Publicado: (2023)

Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris, Marie Olivia, et al.
Publicado: (2017)

The impact of ACE gene polymorphism on the incidence and phenotype of sarcoidosis in rural and urban settings
por: Kieszko, Robert, et al.
Publicado: (2015)

Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2020)

The TT Genotype of the KIAA1524 rs2278911 Polymorphism Is Associated with Poor Prognosis in Multiple Myeloma
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2023)

The Clinical Relevance of Selected Cytokines in Newly Diagnosed Multiple Myeloma Patients
por: Mielnik, Michał, et al.
Publicado: (2023)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

Polymorphisms of Genes Encoding Multidrug Resistance Proteins as a Predictive Factor for Second-Line Docetaxel Therapy in Advanced Non-small Cell Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2016)

Neutrophil-to-Lymphocyte Ratio as a Factor Predicting Radiotherapy Induced Oral Mucositis in Head Neck Cancer Patients Treated with Radiotherapy
por: Homa-Mlak, Iwona, et al.
Publicado: (2021)

Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management
por: Papayannidis, Cristina, et al.
Publicado: (2022)

The Association of GSTT1, GSTM1, and TNF-α Polymorphisms With the Risk and Outcome in Multiple Myeloma
por: Zmorzyński, Szymon, et al.
Publicado: (2019)

Methylation of DROSHA and DICER as a Biomarker for the Detection of Lung Cancer
por: Szczyrek, Michał, et al.
Publicado: (2021)

The Impact of the NOD2/CARD15 Variant (3020insC) and PSMA6 Polymorphism (-8C>G) on the Development and Outcome of Multiple Myeloma
por: Zmorzyński, S., et al.
Publicado: (2020)

The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis
por: Helbig, Grzegorz, et al.
Publicado: (2020)

P1036: REAL-WORLD EFFICACY AND SAFETY OF MIDOSTAURIN-TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS
por: Lübke, Johannes, et al.
Publicado: (2023)

The Relationship of ABCB1/MDR1 and CYP1A1 Variants with the Risk of Disease Development and Shortening of Overall Survival in Patients with Multiple Myeloma
por: Zmorzynski, Szymon, et al.
Publicado: (2021)

P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE
por: Reiter, A., et al.
Publicado: (2022)

Discordant Response of Systemic Mastocytosis Associated With Myelodysplastic Syndrome After Midostaurin and Allogeneic Hematopoietic Stem-cell Transplantation
por: Haas, Marion, et al.
Publicado: (2020)

European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
por: Tzogani, Kyriaki, et al.
Publicado: (2019)

PB2044: TRIAL IN PROGRESS: OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED IN ITALY WITH MIDOSTAURIN (OVIDIO)
por: Grifoni, F. I., et al.
Publicado: (2022)

Systemic Mastocytosis Treatment with Midostaurin: [(18)F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome
por: Burgard, Caroline, et al.
Publicado: (2022)

The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma
por: Popek-Marciniec, Sylwia, et al.
Publicado: (2023)

ACE Insertion/Deletion Polymorphism (rs4646994) Is Associated With the Increased Risk of Multiple Myeloma
por: Zmorzynski, Szymon, et al.
Publicado: (2019)

Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy
por: Weisberg, Ellen, et al.
Publicado: (2017)

Association of Chromosome 17 Aneuploidy, TP53 Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment
por: Popek-Marciniec, Sylwia, et al.
Publicado: (2023)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

An aggressive systemic mastocytosis preceded by ovarian dysgerminoma
por: Tsutsumi, Makiko, et al.
Publicado: (2020)

Anatomical classification of the shape and topography of the stomach
por: Burdan, Franciszek, et al.
Publicado: (2011)

High Level of Irisin as a Marker of Malnutrition in Head and Neck Cancer Patients Subjected to Radiotherapy
por: Homa-Mlak, Iwona, et al.
Publicado: (2022)

Acute urticaria: an extremely rare adverse effect of levonorgestrel-releasing intrauterine system as a possible manifestation of progestogen hypersensitivity syndrome
por: Emeryk-Maksymiuk, Justyna, et al.
Publicado: (2018)

An unusual case of aggressive systemic mastocytosis mimicking hepatic cirrhosis
por: Zhang, Xiao-Yang, et al.
Publicado: (2014)

Aggressive Systemic Mastocytosis in Association with Pure Red Cell Aplasia
por: Karam, Dhauna, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o0e9i2nod5kus1kagja019l90o